What are the chronic diseases of the lungs in children?
The acronym chILD stands for a large number of rare chronic lung diseases in children. The tissue around the alveoli, the interstitium, is affected. The acronym chILD was formed from the initial letters of the English abbreviation children´s interstitial lung disease.
These interstitial lung diseases make breathing more difficult because the alveoli are less elastic than in healthy people. Children are often unable to absorb enough oxygen through the lungs, which they compensate for by breathing more quickly. However, this costs a lot of energy, which is why they are more quickly exhausted and less resilient than their peers. However, the disease has a good prognosis. The children learn very well to live with it or they feel better from year to year. Some children even become symptom-free in the course of time.
Closing the gap – systematic search for new therapies for chILD patients
Since these diseases are so rare, the medical community still knows very little about their causes and courses. In addition, there is no drug yet that has been tested for the specific treatment of chILD. All drugs are currently administered "off label", i.e. outside of the approval on the basis of pure experience. chILD-EU is a project funded by the European Union in which data, images, biosamples (blood, tissue, etc.) of chILD patients are systematically collected. In this way, physicians want to learn more about disease causes, the course of disease, examination techniques and therapy options. At the CPC-M, the group led by Professor Matthias Griese coordinates this collection of data.
Within the framework of chILD-EU, clinically controlled, double-blind studies on the effect of hydroxychloroquine (HCQ) in children with chILD are currently being conducted throughout Europe. They are supported by the DZL in Germany. HCQ is a drug that was previously used to treat malaria.
The study aims to clarify the following questions:
How effective is HCQ compared to placebo in children?
How safe is the medium-term use of HCQ?
What are the risks and benefits of using HCQ?
Learn more about the HCQ study here:
Prof. Dr. Matthias Griese
Dr. von Haunersches Kinderspital
Klinikum der Universität München
Tel: +49 (0)89 4400 57871
Prof. Dr. med. Matthias Kappler
(Deputy Head of Group)
PD Dr. med. Karl Reiter
Dr. med. Jan Ripper
Dr. med. Ingo Pawlita
Dr. med. Maria Forstner
Dr. med. Elias Seidl
Sabine Witt (Public Health)
(Archive and Lab)
Andrea Schams (MTA)
Claudia Eismann (Project management)
Dörthe Neuner (Study coordination)
Hengst M et al., Orphanet J Rare Dis. 2018:
Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood.
Schindlbeck U et al., Hum Mutat., 2018:
ABCA3 missense mutations causing surfactant dysfunction disorders have distinct cellular phenotypes
Griese M. et al., Eur Respir Rev. 2018:
Chronic interstitial lung disease in children
Kinting S et al., Hum Mol Genet., 2018:
Functional rescue of misfolding ABCA3 mutations by small molecular correctors